119 related articles for article (PubMed ID: 3358904)
21. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention.
Supino R; Prosperi E; Formelli F; Mariani M; Parmiani G
Br J Cancer; 1986 Jul; 54(1):33-42. PubMed ID: 3730255
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
23. Abnormally banded chromosomal regions in doxorubicin-resistant B16-BL6 murine melanoma cells.
Slovak ML; Hoeltge GA; Ganapathi R
Cancer Res; 1986 Aug; 46(8):4171-7. PubMed ID: 3731084
[TBL] [Abstract][Full Text] [Related]
24. Can cytotoxic activity of anthracyclines be related to DNA damage?
Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
[TBL] [Abstract][Full Text] [Related]
25. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
26. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Gambacorti-Passerini C; Rivoltini L; Supino R; Rodolfo M; Radrizzani M; Fossati G; Parmiani G
Cancer Res; 1988 May; 48(9):2372-6. PubMed ID: 3258541
[TBL] [Abstract][Full Text] [Related]
28. Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.
Schott B; Vrignaud P; Ries C; Robert J; Londos-Gagliardi D
Br J Cancer; 1990 Apr; 61(4):543-7. PubMed ID: 2331441
[TBL] [Abstract][Full Text] [Related]
29. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
30. DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil.
Delvaeye M; Verovski V; De Neve W; Storme G
Anticancer Res; 1993; 13(5A):1533-8. PubMed ID: 8239532
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
32. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
33. Characterization of resistance to VP-16 in human leukemic cell line.
Saijo Y; Kumano N; Tokue Y; Satoh K; Oizumi K; Motomiya M
Tohoku J Exp Med; 1989 Dec; 159(4):299-306. PubMed ID: 2633408
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
Yin MB; Bankusli I; Rustum YM
Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
[TBL] [Abstract][Full Text] [Related]
35. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
36. Cellular and molecular pharmacology of 4'-epidoxorubicin in HeLa cells. Comparison with its parent drug, doxorubicin.
Cantoni O; Sestili P; Cattabeni F; Geroni C; Grandi M; Giuliani FC
J Cancer Res Clin Oncol; 1989; 115(4):373-8. PubMed ID: 2760101
[TBL] [Abstract][Full Text] [Related]
37. Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin.
Panneerselvam M; Bredehorst R; Vogel CW
Cancer Res; 1987 Sep; 47(17):4601-7. PubMed ID: 3621156
[TBL] [Abstract][Full Text] [Related]
38. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184.
Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK
Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831
[TBL] [Abstract][Full Text] [Related]
39. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
[TBL] [Abstract][Full Text] [Related]
40. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
